| Literature DB >> 26886066 |
Ling Qin1, Xie Jing1, Zhifeng Qiu1, Wei Cao1,2,3, Yang Jiao4, Jean-Pierre Routy2,3,5, Taisheng Li1.
Abstract
Aging is a major risk factor for several conditions including neurodegenerative, cardiovascular diseases and cancer. Functional impairments in cellular pathways controlling genomic stability, and immune control have been identified. Biomarker of immune senescence is needed to improve vaccine response and to develop therapy to improve immune control. To identify phenotypic signature of circulating immune cells with aging, we enrolled 1068 Chinese healthy volunteers ranging from 18 to 80 years old. The decreased naïve CD4+ and CD8+ T cells, increased memory CD4+ or CD8+ T cells, loss of CD28 expression on T cells and reverse trend of CD38 and HLA-DR, were significant for aging of immune system. Conversely, the absolute counts and percentage of NK cells and CD19+B cells maintained stable in aging individuals. The Chinese reference ranges of absolute counts and percentage of peripheral lymphocyte in this study might be useful for future clinical evaluation.Entities:
Keywords: aging; flow cytometry; lymphocyte subsets; reference range
Mesh:
Year: 2016 PMID: 26886066 PMCID: PMC4931839 DOI: 10.18632/aging.100894
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Reference range of T lymphocyte subsets in different age groups
| parameters | All | Young | Middle-aged | Elder | ||
|---|---|---|---|---|---|---|
| N=1068 | N=781 | N=246 | N=41 | |||
| Age (years) | Mean ±SD | 40.5±10.04 | 35.4±4.61 | 50.9±4.50 | 71.6±4.53 | |
| Range | (19-80) | (19-44) | (45-64) | (65-80) | ||
| Sex | Male : Female | 731:337 | 564:217 | 134:112 | 33:8 | 0.000 |
| Lymphocyte counts | Mean ±SD | 2086 ±547 | 2106±535 | 2046±587 | 1946±505 | 0.042 |
| (cells/ul) | 95%CI | 2053-2119 | 2068-2143 | 1972-2119 | 2053-2119 | |
| CD19+ B counts | Mean ±SD | 216 ±99 | 218±97 | 213±106 | 198±112 | 0.383 |
| (cells/ul) | 95%CI | 210-222 | 211-225 | 200-226 | 163-233 | |
| CD19+ B percentage (%) | Mean ±SD | 10.40 ±3.73 | 10.38±3.56 | 10.49±4.02 | 10.17±5.00 | 0.863 |
| 95%CI | 10.18-10.63 | 10.14-10.64 | 9.9810.99 | 8.59-11.75 | ||
| CD16CD56+ NK counts | Mean ±SD | 403 ±220 | 407±215 | 376±214 | 477±305 | 0.012 |
| (cells/ul) | 95%CI | 389-416 | 392-422 | 349-403 | 381-574 | |
| CD16CD56+ NK percentage | Mean ±SD | 19.19 ±8.52 | 19.19±8.10 | 18.38±8.73 | 24.11±12.62 | 0.000 |
| (%) | 95%CI | 18.68-19.70 | 18.62-19.75 | 17.29-19.48 | 20.13-28.09 | |
| CD3+ T counts | Mean SD | 1387 ±414 | 1403±402 | 1368±449 | 1198±399 | 0.006 |
| (cells/ul) | 95%CI | 1362-1412 | 1375-1431 | 1312-1424 | 1071-1323 | |
| CD3+ T percentage | Mean ±SD | 66.44 ±8.58 | 66.62±8.17 | 66.67±8.96 | 61.73±12.12 | 0.002 |
| (%) | 95%CI | 65.93-66.96 | 66.05-67.19 | 65.55-67.80 | 57.91-65.56 | |
| CD3+CD4+T counts | Mean ±SD | 694 ±202 | 690±227 | 708±241 | 699±281 | 0.565 |
| (cells/ul) | 95%CI | 680-708 | 674-706 | 677-738 | 610-787 | |
| CD3+CD4+/CD3+ | Mean ±SD | 33.48 ±7.33 | 32.91±6.95 | 34.89±7.80 | 35.81±9.80 | 0.000 |
| (%) | 95%CI | 33.04-33.92 | 32.43-33.40 | 33.91-35.87 | 32.72-38.90 | |
| CD3+CD8+T counts | Mean ±SD | 589 ±244 | 605±234 | 561±269 | 448±235 | 0.000 |
| (cells/ul) | 95%CI | 574-604 | 589-621 | 528-595 | 374-522 | |
| CD3+CD8+/CD3+ | Mean ±SD | 27.96 ±7.67 | 28.52±7.27 | 26.97±8.12 | 23.09±9.91 | 0.000 |
| (%) | 95%CI | 27.50-28.42 | 28.01-29.03 | 25.96-27.99 | 19.96-26.21 | |
| CD4+CD45RA- | Mean ±SD | 430 ±156 | 419±147 | 459±168 | 472±212 | 0.000 |
| (cells/ul) | 95%CI | 421-440 | 408-429 | 438-480 | 406±539 | |
| CD4+CD45RA-/CD4+ | Mean ±SD | 62.81 ±11.94 | 61.52±11.17 | 65.282±12.72 | 69.28±15.77 | 0.000 |
| (%) | 95%CI | 62.09-63.52 | 60.73-62.30 | 64.23-67.42 | 64.30-7.25 | |
| CD4+CD45RA+ | Mean ±SD | 264 ±138 | 271±133 | 249±147 | 226±165 | 0.000 |
| (cells/ul) | 95%CI | 256-272 | 262-280 | 230-267 | 174-278 | |
| CD4+CD45RA+/CD4+ | Mean ±SD | 37.19 ±11.94 | 38.48±11.17 | 34.18±12.72 | 30.73±15.78 | 0.017 |
| (%) | 95%CI | 36.48-37.91 | 37.70-39.27 | 32.58-35.77 | 25.74-35.71 | |
| CD4+CD45RA+CD62L+ | Mean ±SD | 240 ±129 | 247±125 | 221±132 | 206±160 | 0.004 |
| (cells/ul) | 95%CI | 232-247 | 239-256 | 204-237 | 156-256 | |
| CD4+CD45RA+CD62L+/CD4+ | Mean ±SD | 33.87±11.80 | 35.24±11.16 | 30.55±12.16 | 27.82±15.41 | 0.000 |
| (%) | 95%CI | 33.17-34.58 | 34.45-36.02 | 29.03-32.08 | 22.95-32.68 | |
| CD4+CD28+ | Mean ±SD | 617 ±210 | 619±206 | 616±212 | 597±271 | 0.816 |
| (cells/ul) | 95%CI | 604-630 | 604-633 | 589-642 | 512-683 | |
| CD4+CD28+/CD4+ | Mean ±SD | 89.18 ±8.44 | 89.88±7.47 | 87.56±10.01 | 85.59±12.52 | 0.000 |
| (%) | 95%CI | 88.68-89.69 | 89.36-90.41 | 86.30-88.82 | 81.64-89.54 | |
| CD8+CD28+ | Mean ±SD | 329 ±132 | 348±129 | 290±121 | 191±115 | 0.000 |
| (cells/ul) | 95%CI | 321-337 | 339-357 | 274-305 | 155-228 | |
| CD8+CD28+/CD8+ | Mean ±SD | 57.71 ±14.17 | 59.41±13.38 | 54.76±14.86 | 43.16±13.50 | 0.000 |
| (%) | 95%CI | 56.86-58.56 | 58.47-60.35 | 52.89-56.62 | 38.90-47.42 | |
| CD8+HLA-DR+ | Mean ±SD | 135 ±98 | 130±97 | 148±102 | 145±92 | 0.038 |
| (cells/ul) | 95%CI | 129-141 | 124-137 | 135-161 | 116-174 | |
| CD8+HLA-DR+/CD8+ | Mean ±SD | 22.38 ±11.08 | 20.78±10.55 | 25.77±11.18 | 32.59±10.34 | 0.000 |
| (%) | 95%CI | 21.72-23.05 | 20.04-21.52 | 24.37-27.18 | 29.33-35.85 | |
| CD8+CD38+ | Mean ±SD | 184 ±111 | 202±112 | 149±92 | 57±49 | 0.000 |
| (cells/ul) | 95%CI | 178-191 | 194-210 | 138-161 | 42-73 | |
| CD8+CD38+/CD8+ | Mean ±SD | 31.91 ±14.49 | 34.05±13.53 | 28.25±15.35 | 13.02±6.75 | 0.000 |
| (%) | 95%CI | 31.04-32.78 | 33.10-35.00 | 26.32-30.18 | 10.89-15.15 | |
| CD4+/CD8+ | Mean ±SD | 1.32 ±0.59 | 1.25±0.48 | 1.45±0.69 | 1.91±1.19 | 0.000 |
| (%) | 95%CI | 1.29-1.36 | 1.22-1.29 | 1.37-1.54 | 1.54-2.29 | |
Figure 1Age related change of CD3+ cell (A), CD3+CD8+ (B), CD4+CD45RA+ cell (C), CD4+CD45RA+CD62L+ cell (D), CD4+CD28+ /CD4+ (E) and CD8+CD28+/CD8+ (F).
Figure 2Reverse age related trend of naive CD4+ (A) and memory CD4+ (B), CD8+HLA-DR ratio (C) and CD8+CD38+ ratio (D).
Age distribution by every decade
| Younger than 25 | 25—34 | 35—44 | 45—54 | 55—64 | 65—74 | 75 and above | |
|---|---|---|---|---|---|---|---|
| number | 7 | 312 | 462 | 186 | 60 | 28 | 13 |
| % in whole | 0.65 | 29.21 | 43.26 | 17.42 | 5.62 | 2.62 | 1.22 |
Figure 3Linear diagrams showed age-related changes by decade for lymphocyte subsets of (A) total lymphocyte cells, CD19+ (B) cell, CD16CD56+ NK cell and CD3+ T cell B CD3+ T cell, CD4+ T cell and CD8+ T cell; (C) CD4+CD45RA−, CD4+CD45RA+ and D4+CD45RA+CD62L+ (D) CD4+CD28+, CD8+CD28+ (E) CD8+HLA.DR+/CD8+ and CD8+CD38+/CD8+ (F) CD4+/CD8+.
Reference range of T lymphocyte subsets in different gender
| Male | Female | ||||
|---|---|---|---|---|---|
| Parameters | Mean ±SD | 95%CI | Mean ±SD | 95%CI | |
| CD19+ B counts (cells/ul) | 223.5±105.40 | 129.95-315.75 | 215.7±98.45 | 121.31-276.50 | 0.001 |
| CD19+ B percentage (%) | 10.2±3.63 | 6.55-13.84 | 10.3±3.59 | 7.13-14.20 | 0.031 |
| CD16+CD56+ NK counts(cells/ul) | 448.0±223.25 | 244.49-650.87 | 407.5±216.91 | 160.72-470.68 | <0.001 |
| CD16+CD56+ NK percentage (%) | 20.4±8.33 | 12.20-28.81 | 19.3±8.21 | 9.62-23.73 | <0.001 |
| CD3+ T counts (cells/ul) | 1438.6±418.98 | 1031.80-1845.75 | 1394.0±417.15 | 916.46-1672.80 | <0.001 |
| CD3+ T percentage (%) | 65.4±8.57 | 56.55-74.40 | 66.4±8.39 | 60.62-76.35 | <0.001 |
| CD3+CD4+ counts (cells/ul) | 696.0±232.80 | 478.02-912.79 | 688.2±228.78 | 466.85-874.61 | 0.139 |
| CD3+CD4+/CD3+ (%) | 31.8±6.83 | 24.88-38.74 | 33.0±6.94 | 29.21-42.21 | <0.001 |
| CD3+CD8+ counts (cells/ul) | 631.1±254.60 | 389.50-873.19 | 597.5±246.38 | 328.11-716.92 | <0.001 |
| CD3+CD8+/CD3+ (%) | 28.5±7.92 | 20.64-36.40 | 28.2±7.60 | 20.70-34.31 | 0.125 |
| CD4+CD45RA− (cells/ul) | 429.0±156.34 | 286.61-570.10 | 424.6±150.57 | 289.36-541.15 | 0.347 |
| CD4+CD45RA−/CD4+ (%) | 62.3±11.53 | 50.07-74.79 | 62.5±11.50 | 51.16-74.96 | 0.390 |
| CD4+CD45RA+ (cells/ul) | 267.0±133.68 | 142.48-391.46 | 263.6±134.54 | 133.24-377.01 | 0.143 |
| CD4+CD45RA+/CD4+ (%) | 37.7±11.53 | 25.61-49.91 | 37.5±11.50 | 25.04-49.13 | 0.413 |
| CD4+CD45RA+CD62L+ (cells/ul) | 242.8±124.86 | 126.60-359.19 | 240.0±126.47 | 117.93-347.58 | 0.160 |
| CD4+CD45RA+CD62L+/CD4+ (%) | 34.4±11.48 | 22.26-46.82 | 34.2±11.45 | 21.95-45.72 | 0.470 |
| CD4+CD28+ (cells/ul) | 616.5±204.90 | 423.33-808.88 | 611.5±205.14 | 410.02-790.52 | 0.228 |
| CD4+CD28+/CD4+ (%) | 89.1±8.38 | 79.76-98.40 | 89.2±8.16 | 80.89-98.14 | 0.425 |
| CD8+CD28+ (cells/ul) | 349.9±132.85 | 221.31-479.19 | 336.0±130.06 | 189.24-422.56 | <0.001 |
| CD8+CD28+/CD8+ (%) | 57.7±14.01 | 43.00-72.51 | 58.4±13.80 | 45.18-75.25 | 0.017 |
| CD8+HLA-DR (cells/ul) | 147.3±102.74 | 58.20-236.70 | 138.0±99.20 | 47.78-184.00 | <0.001 |
| CD8+HLA-DR/CD8+ (%) | 22.7±10.74 | 11.94-33.92 | 22.4±10.72 | 11.65-32.10 | 0.267 |
| CD8+CD38+ (cells/ul) | 191.6±111.9 | 99.28-280.28 | 190.0±108.43 | 95.84-277.46 | 0.535 |
| CD8+CD38+/CD8+ (%) | 31.2±13.16 | 18.91-43.27 | 32.7±13.74 | 22.61-50.00 | 0.552 |
| CD4+/CD8+ ratio (%) | 1.2±0.54 | 0.75-1.71 | 1.3±0.54 | 0.93-1.87 | <0.001 |
Relationship between age and T lymphocyte subsets in regression analysis
| Age & T lymphocyte subsets | Unstandardized coefficient | Standard Error | |
|---|---|---|---|
| CD19+ B counts | −6.129 | 5.667 | 0.280 |
| CD19+ B percentage | −0.409 | 0.212 | 0.818 |
| CD16CD56+ NK counts | 8.708 | 12.083 | 0.471 |
| CD16CD56+ NK percentage | 0.987 | 0.474 | 0.057 |
| CD3+ T counts | −56.889 | 23.432 | 0.015 |
| CD3+ T percentage | −1.329 | 0.482 | 0.006 |
| CD3+CD4+T counts | 12.45 | 13.28 | 0.349 |
| CD3+CD4+T percentage | 1.427 | 0.402 | 0.000 |
| CD3+CD8+T counts | −52.044 | 13.611 | 0.000 |
| CD3+CD8+T percentage | −2.010 | 0.433 | 0.000 |
| CD4+CD45RA- | 34.761 | 8.856 | 0.000 |
| CD4+CD45RA− percentage | 4.12 | 0.67 | 0.000 |
| CD4+CD45RA+ | −22.304 | 7.841 | 0.005 |
| CD4+CD45RA+ percentage | −4.119 | 0.670 | 0.000 |
| CD4+CD45RA+CD62L+ | −23.870 | 7.391 | 0.001 |
| CD4+CD45RA+CD62L+ percentage | −4.239 | 0.662 | 0.000 |
| CD4+CD28+ | −6.776 | 12.015 | 0.573 |
| CD4+CD28+/CD4+ | −2.333 | 0.476 | 0.000 |
| CD8+CD28+ | −65.54 | 7.214 | 0.000 |
| CD8+CD28+/CD8+ | −6.501 | 0.781 | 0.000 |
| CD8+HLA-DR+ | 15.939 | 5.522 | 0.004 |
| CD8+HLA-DR+/CD8+ | 5.625 | 0.606 | 0.000 |
| CD8+CD38+ | −62.639 | 6.036 | 0.000 |
| CD8+CD38+/CD8+ | −8.518 | 0.765 | 0.000 |
| CD4+/CD8+ | 0.248 | 0.033 | 0.000 |
comparison lymphocyte subsets of present study with other studies
| Area | country | Year | Num | Age range | Male: Female | CD3+ CD4+ | CD3+ CD8+ | CD4+/CD8+ ratio | CD16+CD56+ | CD19+ |
|---|---|---|---|---|---|---|---|---|---|---|
| (years) | (cells/ul) | (cells/ul) | (cells /ul) | (cells /ul) | ||||||
| Asia | China | Present | 1068 | 19-80 | 731:337 | 694 | 589 | 1.32 | 403 | 216 |
| motherland | study | |||||||||
| Singapore | 2004 | 232 | 10-69 | 104:128 | 838 | 642 | 1.43 | 419 | 353 | |
| Iran | 2011 | 233 | 20-45 | 150:83 | 827 | 522 | 1.61 | 248 | 332 | |
| HongKong | 2013 | 273 | 17-59 | 150:123 | 760 | 515 | 1.59 | 229 | 298 | |
| Korea | 2014 | 294 | 33-61 | 139:155 | 787 | 479 | 1.81 | 300 | 203 | |
| Africa | Ethiopia | 1999 | 485 | 15-45 | 280:205 | 775 | 747 | 1.2 | 250 | 191 |
| Nigeria | 2009 | 2570 | 18-80 | 1363:1207 | 847 | 435 | 2.3 | - | - | |
| Morocoan | 2012 | 242 | 19-49 | 220:22 | 871 | 637 | 1.37 | 211 | 59 | |
| Kenyan | 2013 | 315 | 16-60 | 222:85 | 920 | 646 | 1.57 | - | - | |
| America | Mexico | 2013 | 400 | 20-40 | 200:200 | 818 | 528 | 1.5 | - | - |
| Florida | 2014 | 50 | 31-67 | 25:25 | 1003 | 590 | 1.8 | 214 | 256 | |
| Brazil | 2015 | 238 | 16-56 | 134:104 | 844 | 555 | 1.52 | 234 | 252 | |
| Europe | Italy | 1999 | 968 | 18-70 | 532:436 | 940 | 551 | 1.71 | 278 | 230 |
| Switzerland | 2004 | 70 | 24-70 | 44:26 | 691 | 343 | 2.1 | 184 | 170 | |
| German | 2005 | 100 | 19-85 | 50:50 | 870 | 460 | 1.9 | 280 | 220 |